analyzing circulating tumor dna to determine remission in patients with lymphoma
Published 7 months ago • 103 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:38
using circulating tumor dna in lymphoma: clinical trials & clinical practice
-
3:05
the clinical use of circulating tumor dna in t-cell lymphomas
-
16:37
panel discussion on new technologies in lymphoma - the applications of circulating tumor dna
-
1:37
the role of ctdna in hodgkin lymphoma
-
1:28
the remaining hurdles for using ctdna in lymphoma
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:25
understand ctdna testing
-
11:43
will knowledge of the molecular pathology of lymphoma improve clinical trials?
-
2:43
interim analysis of the elm-2 study: odronextamab in patients with r/r follicular lymphoma
-
1:15
biomarkers being explored in hodgkin lymphoma: the role of ctdna
-
2:33
linking the diagnosis-to-treatment interval with ctdna
-
2:42
the value of circulating tumor cells for the staging of patients with ndmm
-
3:56
phase i study of tinostamustine in pre-treated patients with r/r hodgkin lymphoma
-
1:01
pitfalls in the diagnosis of lymphoid malignancies: interpreting pet scans
-
3:59
using enhanced ctdna profiling to identify molecular determinants of response in r/r mcl
-
3:54
the use of tarc as a diagnostic biomarker in hodgkin lymphoma
-
3:10
the potential for early identification of relapse in dlbcl using serial ctdna sampling
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
3:07
the role of bridging and timing in car-t
-
2:12
results from a phase i trial of tinostamustine in patients with r/r classical hl